Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370887 · ClinicalTrials.gov registry record · Phase 2
AZD8601 Study in CABG Patients
A Phase 2 study of Heart Failure, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 10
- Study locations
NCT03370887 is a Phase 2 study of Heart Failure that has completed, run by AstraZeneca. The registered enrollment target is 11 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 2 states.
The verdict
NCT03370887, a Phase 2 study of Heart Failure, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacements are needed). The objective is to investigate safety and tolerability of AZD8601 following epicardial injection in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery with moderately impaired systolic function. At Visit 3 patients will receive either AZD8601 or placebo as epicardial injections and will then be followed up at 14 days (telephone visit) and 1, 3 and 6 months (on-site) post-surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD8601
Study Locations (10)
Other
- Research Site - Kuopio
- Research Site - Tampere
- Research Site - Turku
- Research Site - München
- Research Site - München
- Research Site - Amsterdam
- Research Site - Groningen
- Research Site - Gothenburg
- Research Site - Uppsala
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-02-05 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03370887
The ClinicalTrials.gov registry entry for NCT03370887 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03370887 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Other, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03370887 about?
NCT03370887 is a clinical study titled "AZD8601 Study in CABG Patients". This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacem...
What is the current status of trial NCT03370887?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-02-05. Estimated completion is 2021-06-30.
What conditions does trial NCT03370887 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03370887?
The interventions under investigation include: Placebo (DRUG), AZD8601 (DRUG).
Who is sponsoring clinical trial NCT03370887?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03370887 being conducted?
This trial has 10 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.